Compare Mitsubishi UFJ Financial Group Inc. Common Stock (MUFG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mitsubishi UFJ Financial Group Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? Mitsubishi UFJ Financial Group Inc. Common Stock trades at $21.65 (market cap $247.53B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Mitsubishi UFJ Financial Group Inc. Common Stock is far larger — about 66.2× Tango Therapeutics Inc.'s market cap, and Mitsubishi UFJ Financial Group Inc. Common Stock pays a 2.46% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mitsubishi UFJ Financial Group Inc. Common Stock for 2 Days and Tango Therapeutics Inc. for 0 Days on average.
| MUFG | TNGX | |
|---|---|---|
Market Cap | $247.53B | $3.74B |
Volume | 3,196,989 | 3,438,781 |
Sector | Financials | Health |
52-Week High | $24.13 | $32.90 |
52-Week Low | $14.77 | $7.50 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $28.41T | $2.76B |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MUFG trades at $22.40, up 0.22% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.45 exceeding the $0.35 estimate. Fundamentals show robust profitability with a 34.22% net income margin and 12.6% ROE, while valuation ratios like a P/E of 14.99 appear reasonable. Recent news highlights a partnership with SkyDrive for eVTOL feasibility studies and positive analyst momentum coverage.
The outlook is supported by earnings momentum and a 100% buy rating from analysts, but risks include a high debt-to-asset ratio of 5.81 and significant negative cash flow trends. Investor sentiment is optimistic due to strong quarterly results and institutional interest, though technical weakness and macroeconomic sensitivity pose near-term challenges.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Mitsubishi UFJ Financial Group Inc. Common Stock
Mitsubishi UFJ Financial Group is a Japanese financial services company providing banking, lending, securities, and asset management services. Its businesses serve individuals, companies, and institutions worldwide.
Read more on MUFG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
